European Biotechnology News Science & Industry
October 2012
II European Biocapital
SPECIAL 35_EBSIN10_12_Special_Titel_pad.indd 1
02.10.2012 18:16:56 Uhr
BUILDING VALUE THROUGH PARTNERSHIPS
BIO-EUROPE
®
18TH ANNUAL INTERNATIONAL PARTNERING CONFERENCE
2012
Online Pa r tnering star ts Oc tober 1 !
NOVEMBER 12–14, 2012 HAMBURG, GERMANY CCH CONGRESS CENTER HAMBURG BIO-Europe® is Europe’s largest partnering conference, serving the global biotechnology industry. The conference annually attracts international leaders from biotech, pharma and finance along with the most promising start-ups and emerging companies. It is the “must attend” event for getting business done in the biotech industry.
© 2012 EBD Group AG
For further information, please view our conference website at www.ebdgroup.com/bioeurope
BEU12 104 EBN 210x275.indd 38_EBSIN10_12_EBD.indd 1 1
02.10.201203.08.12 18:18:0615:28 Uhr
Nº 10 | Volume 11 | 2012
Euro|Biotech|News
39
Special Intro
Biocapital in Europe – a mixed bag Europe’s biotechnology companies are on the move, and nowhere is that better illustrated than by their growing need for money – up to US$5.7bn this year, according to Biocentury. A look at financing numbers from the first half of 2012 makes it clear that venture and public capital will not be able to satisfy that demand. It’s a tough period for European biotechs looking for much-needed financing. Although a number of fresh biotech VC funds were set up this year with strong support from public sources, the money doesn’t seem to have trickled down to many companies yet. This fact is illustrated by Munich-based Proteros Biostructures GmbH – the lucky number ten in the largest VC
funding in the first half of 2012. But even it only landed a5m (see below). There’s stiff global competition to receive the blessings of remaining active VC funds. For Rainer Strohmenger, Funds Manager for Wellington Partners, investing in biotech is still currently only a secondary option: "Shorter development times and lower amounts of money will be invested be-
fore market launches make medtech one of the more interesting areas,” he said in an interview with EuroBiotechNews (see p. 40). But there are some signs of hope. In September, Germany’s CureVac AG received about a80m from its patron Dietmar Hopp – one of the largest European VC rounds for years. Together with Thomas Strüngmann, who set up and sold Hexal AG for a6.5bn to Novartis, Hopp is the most active investor in the German-speaking Europe. Several family offices follow his lead. While the stock market generally hasn’t provided good news for biotech in most European countries, Belgium and France continue to perform well (see p. 21). This year has seen two initial public offerings in France, from DBV Technologies and Adocia (see p. 40). However, individual amounts of money collected were small. In terms of secondary financings, Vernalis (UK) and Thrombogenics (Belgium) lead the pack with amounts above and beyond a100m. As the market remains as unpredictable as ever, it will be interesting to see what the second half of 2012 brings. D
Top 10 public and private financing deals for European biotech companies in the first half of 2012 Volume (Euro)
Comment
A Agendia NV (NL)
50.0m
Private placement to increase marketing activities.
A Magnisense SA (F)
44.3m
Rusnano and existing shareholders invest in production facilities in Russia.
A ADC Therapeutics (CH)
38.8m
Celtic Therapeutics launches new ADC company in Lausanne.
A Probiodrug AG (D)
15.0m
Edmond de Rothschild and others invest to bring Alzheimer drug to clinical proof.
A Galecto Biotech AB (DK)
10.0m
Sunstone and SEED Capital expand Series A round.
A Pharnext SAS (F)
8.0m
Second financing round for French CNS specialist.
A Apogenix GmbH (D)
7.5m
Dietmar Hopp invests in further clinical development of Apogenix‘ drug candidates.
A Vivia Biotech SL (ES)
7.3m
Spanish cancer specialist receives funding from Andalusian and European sources.
A Telormedix SA (CH)
6.0m
Swiss specialist for cancer and inflammatory diseases receives venture capital.
A Proteros Biostructures GmbH (D)
5.0m
Proteros convinces BayBG to support company re-alignment and service expansion.
Public Company
Volume (Euro)
Comment
A Vernalis plc (UK)
80.0m
Investors support change to new business model as a specialty pharma.
A Thrombogenics NV (B)
77.8m
Company sought and found new money to fund US launch of ocriplasmin.
A Swedish Orphan Biovitrum AB (S)
68.0m
Swedish company restructures its debt.
A DBV Technologies SA (F)
41.0m
IPO at Euronext.
A Algeta ASA (N)
35.4m
Algeta sells fresh shares, investor Abingworth old ones.
A Tissue Regenix (UK)
30.0m
Regmed specialist funds development activities.
A Adocia SAS (F)
27.4m
IPO at Euronext.
A Cytos AG (CH)
26.4m
Cytos AG receives rescue package from existing and new investors.
A Clavis Pharma ASA (N)
23.9m
Pivate placement to fund development operations
A Wilex AG (D)
21.2m
Dietmar Hopp supports cancer antibody specialist with bridge financing.
39_EBSIN10_12_Special_intro_pad.indd 39
© BIOCOM AG
Private Company
05.10.2012 12:15:25 Uhr
40
Nº 10 | Volume 11 | 2012
Euro|Biotech|News
special Adocia
Successful IPO in challenging times IPOs have stalled completely in Europe... except in France. Two companies – DBV Technologies and Adocia – have gone public on the NYSE Euronext Paris so far in 2012, although the amount of money they managed to collect was significantly lower than it would have been in pre-crisis days. Gérard Soula, President and CEO of Adocia, told EuroBiotechNews howhis firm is doing on Europe’s biotech capital market in troubling times.
Gérard Soula, President & CEO of Adocia, has a strong track record in innovation in the field of biotechnology. He was the CEO for 15 years at Flamel Technologies, a biotech company based in Lyon that he founded. Under his leadership, Flamel carried out an IPO and a second offering on the NASDAQ. By the time Soula left, the company had 250 employees, US$100m in cash in the bank and a market capitalisation of US$500m. Before that, he was the director of scientific research at French chemicals and pharmaceuticals company Rhône Poulenc, and was awarded the Rhône Poulenc Innovation Prize for his invention of a new type of catalyst based on molecular self-assembly. More recently, he has received the Chaptal Prize for his contributions to the development of pharmaceutical innovations. Gérard Soula is the co-author of 138 patents.
40-41_EBSIN_10_12_Special_Soula_pad.indd 40
Adocia is a biotechnology company specialised in the development of best-inclass medicines with already-approved therapeutic proteins. Today, the company is focusing its activity on insulin therapy and the treatment of diabetic foot ulcer, one of the main complications of diabetes. Diabetes has reached pandemic proportions, currently affecting more than 366 million people, touching not only developed countries but also increasingly emerging countries. Adocia’s strategy is to develop efficient treatments but in an affordable way for everyone. The French biotech sector has analysed the global pharmaceutical industry, which is currently going through major changes as it searches for new models. The two determinant pharmaco-economic factors are speed and the cost of technological innovation. Our business model is to develop our innovative products up to “proof-ofconcept” and then to license them to big biopharma.
Getting through a crucial year 2011 was a pivotal year in the deployment of Adocia’s corporate plan – one that saw us achieve key milestones. Among them was the closing of a first partnership agreement on an ultra-fast insulin analog formulation. This agreement was signed with a leading player in the global pharmaceutical industry, and it led to a payment of US$10m in up-front and a po-
tential US$156m in milestone payments. Also significant was the fact that the partnership demonstrated the uniqueness of Adocia’s BioChaperone® platform, and validated its business model. The good news is that partnership for innovative products is welcome by a Big Pharma hungry for innovation.
IPO: 27.5 million euros raised The results of two recently-announced Phase II clinical studies on fast-acting human insulin and on the treatment of diabetic foot ulcer have also been a major step up for Adocia in illustrating and validating the potential of our BioChaperone technology. The latest key event was the registration of six new patents protecting Adocia’s technology for diabetic foot ulcer treatment, thus reinforcing our competitive position. The major development this year has been our successful Initial Public Offering, the first in 2012 on the NYSE Euronext Paris, in what remains a challenging market environment. This adventure was made even more stressful for management since the stock market had been more or less closed for about a year to biotech companies. That made it difficult to get clear feedback on investor interest in our company. The company raised a27.5m. During the road show, our management saw great interest from investors. That’s because BioChaperone technology applied to both our projects and potential applications such as insulin therapies, which represent a market of more than US$17bn worldwide. The other key factor in our success was our business model, which has the advantage of dealing with Big Pharma early in the product development process, generating revenues long before product approval and consequently consuming less capital. Since its inception in 2006, Adocia has raised a55.3m (including the IPO). The company still had a34m in cash at the end of the second quarter of 2012. Management doesn’t expect that we will need to raise more cash to execute our business plan for at least three years.
04.10.2012 11:47:33 Uhr
ce
hem
istr
y
om
e nic
mu
ati
on
n
tio
Nº 10 | Volume 11 | 2012
special
Adocia Management at NYSE Euronext after the IPO Since the IPO, the company has announced two major positive clinical results related to its ultra-fast human insulin project, as well as the clinical trials related to the treatment of diabetic foot ulcers. Adocia also announced the issuance by the American US Patent and Trademark Office and the European Patent Office of a patent protecting our formulations for the treatment of the condition.
Controlling the burn rate More recently, Adocia published financial results for the first half of 2012, which showed an increase in operational revenues of more than 90%, with expenses clearly under control. In short, the announcements to date are in line with expectations. More than ever, it is crucial to obtain unique product performance, but the burn rate has to be tightly controlled due to market conditions.
A strong but responsible financial position Thanks to the IPO, the company has the financial resources to develop its projects over the long term and is thus able to create value for its shareholders. In addition, Adocia has gained visibility with biopharmaceutical companies by publishing its financial accounts and through its policy of transparency. We prepared the IPO last year together with the help of ex-
40-41_EBSIN_10_12_Special_Soula_pad.indd 41
ternal financial auditors and legal counsel. But since its inception, Adocia has always presented its results and structured itself in a way that was already compliant with the rules governing public companies – which made the process easier. The company has seen its market-cap significantly decrease since listing, despite three positive announcements. In response, our management has organised meetings with shareholders to update its portfolio of activity and reiterate that potential value is based on partnerships and clinical trial achievements, which take time to happen.
Delivering on promises In many ways, therefore, the last few months have helped our company to take on a new dimension. Our business model – that of a biotechnology company that requires low capital and strongly focuses on research and innovation – has proved successful. Adocia will continue to carry out the development of its projects by strengthening its organisation and management while continuing to control general expenses and manage costs in order to be able to dedicate its resources to its all-important R&D activities. With its highquality portfolio of patents and promising projects, as well as a strong financial structure and the commitment of its team day in, day out, the company will continue to make all necessary efforts to earn its partners’ and shareholders’ long-term trust. B
rgy on Ene omati re s wa t u A tonic Sof t l Pho str ia u Ind
a nic tr y mu e mis com erce enc ience & Che e e i l r c e a S y Sc tw mm &T Life er ial nolog Sof rnet E-co t e d Ma otech Int ia an n d Na Me
ion
nce
cat uni e
y
noi
tac
inu ecr e
Achieve innovation, , n shape the future Start shot for young technology companies High Tech Gruenderfonds is your partner for Seed Stage investing. We help out young, high potential startups in the early phases of technology and product development, as well as successful launching. Our assistance is not limited to our cash investments, instead we strive to add long term added-value to portfolio companies through our extensive network of professional and our accredited coaches.
Schlegelstraße 2 | 53113 Bonn Phone: +49 (0)228-82300-100 Fax: +49 (0)228-82300-050 E-Mail: info@htgf.de ht tp: // www.high-tech-gruenderfonds.de INVESTORS OF HIGH-TECH GRUENDERFONDS II
04.10.2012 11:47:43 Uhr
y
,s
.
ed
42
Nº 10 | Volume 11 | 2012
Euro|Biotech|News
special Interview
“70 million euros are a good sign” Pan-European investor Wellington Partners has closed its fourth life sciences fund. In an interview with EuroBiotechNews, General Partner Rainer Strohmenger talked about Wellington’s investment strategy, and why he currently prefers medtech investments.
Euro|BioTech|News
?
Mr. Strohmenger, how would you classify your new a70m life sciences fund?
! Strohmenger: I think the closing sends a very positive signal for the life sciences! The new fund is significantly larger than its predecessor, which was at the end of its investment term. Raising new money means a seamless transition from one fund to another. In these troubling times, that can’t be taken for granted. Euro|BioTech|News
?
How would you describe your investment strategy for it?
! Strohmenger: We will invest preferably in medical technology and diagnostics, and only very selectively in the development of therapeutics. It is very challenging to fund such companies with the a7m-a10m that we will reserve for each investment. However, we’re not excluding the idea of funding drug developers if we see an outstanding opportunity. Euro|BioTech|News
?
And geographically?
! Strohmenger: Europe and especially the German-speaking region will be at the centre of our activities, with more than 50% of the invest-
42_EBSIN10_12_Special_Interview_pad.indd 42
ed capital. In fact, this is not far from the actual market share that Germany, Austria and Switzerland represent. From our point of view, it is also easier to lead investments successfully when they are close to your front door.
Euro|BioTech|News
?
What is the final target size of your fund and when will it be reached?
! Strohmenger: We’re optimistic that we’ll achieve our overall final size goal of a120m within the next few months – we have a large investor pipeline. Many people wait for the first closing, as this is the sign that the fund will indeed become a reality. Today, many fundraising attempts are open-ended, and that leaves their investors with a lot of uncertainty. Euro|BioTech|News
?
Where’s your investment sweet spot?
! Strohmenger: We are looking for innovative companies that are developing diagnostic methods or medical devices that seek to address a large medical need. Their products need to be better and/or ideally cheaper than the gold standard. A best-case scenario contains an established reimbursement system as well. These companies benefit from the more favourable regulatory environment in Europe compared to the United States.
Rainer Strohmenger joined Wellington Partners in 1997, and became a Partner in December 2000. His fifteen years of investment activity have involved financing some of the most successful European biotech, medtech, and diagnostics companies. In the late 1990s, Strohmenger co-managed Wellington’s investment in Swiss biotech player Actelion, today a listed company with a market cap of more than four billion euros. He was also responsible for the investment company’s investments in both immatics and mtm laboratories, which was purchased for more than a130m by Roche. Prior to joining Wellington, Strohmenger was involved in medical research with a primary focus on cardiovascular physiology, as well as in research on health economics at the LudwigMaximilian University in Munich. He holds a PhD in medicine and a MSc in economics, and was trained at MIT’s Entrepreneurship Center in Boston.
Euro|BioTech|News
?
How would you compare the biopharma and the medtech markets?
! Strohmenger: The biotech exit and licensing model is in a very interesting period, because Big Pharma is cutting down its own research and increasingly relies on external innovation. The trade sale market in medical devices is already pretty much established, especially in the US. It is smaller than the biopharma space, but new players like Samsung or Sony are entering the club. I believe that the number of acquisitions in Europe will rise. A company like Medtronic has achieved world market leader status only by acquiring technologies. Combined with shorter development times and lower amounts of money to be invested until market launch, medtech is one of the most interesting areas.
04.10.2012 11:48:13 Uhr
6th Berlin Conference on IP in Life Sciences
Companion Diagnostics
© Netherlands Embassy Berlin, Christian Richter
Save the Date
8 February 2013, 9:00 a.m., Embassy of the Netherlands in Berlin, Germany Why attend? The patent cliff and an increasingly payer-driven environment are problems for the life sciences industry. Specialised treatments have thus become a critical asset for pharma. Drug diagnostics combinations – so called companion diagnostics – offer companies the ability to develop targeted drugs with the potential for greater efficacy, accelerated regulatory approval and better reimbursement. Thus, developing treatments without suitable diagnostics has become an expensive form of Russian roulette. But, this joint process is complex. The challenges have created new forms of cooperation between pharma, biotechs and diagnostics service companies and resources needed to cope with giant amounts of data. The reward is huge: analysts forecast new billion dollar markets. This BIOCOM Event offers a unique opportunity to gain insight into the converging strategies of pharma and diagnostics companies. Leading experts in the field of biomarkers, diagnostics, IT and drug development will share their knowledge on how to successfully develop and market new concepts. More information can be found at www.biocom.de/events Sponsors:
Supporting Partners:
Media Partner: European Biotechnology Net work
Organisation: BIOCOM AG | Lützowstraße 33–36 | 10785 Berlin www.biocom.de | events@biocom.de | Tel. +49 (0)30 264921-53 | Fax +49 (0)30 264921-66
43_EBSIN10_12_IP-Anzeige.indd 1 6th-IP-Ad_210x275.indd 87
12:20:15 Uhr 04.10.2012 12:18:00